Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.6, Iss.13, 2005-10, pp. : 2301-2313

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oral and Intravenous Ibandronate in the Management of Postmenopausal Osteoporosis: A Comprehensive Review

Current Pharmaceutical Design, Vol. 11, Iss. 28, 2005-11 ,pp. : 3711-3728

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Utility of a Pharmacostatistical Model for Ibandronate in Postmenopausal Osteoporosis

Current Drug Metabolism, Vol. 7, Iss. 7, 2006-10 ,pp. : 827-836

Bentham Science Publishers

Access to resources Recommend Favorite

Ibandronate: A Review of its Use in the Management of Postmenopausal Osteoporosis

By Frampton James E. Perry Caroline M.

Drugs, Vol. 68, Iss. 18, 2008-01 ,pp. : 2683-2707

Adis International

Access to resources Recommend Favorite

Treating Osteoporosis with Bisphosphonates and Addressing Adherence: A Review of Oral Ibandronate

By Chesnut Charles H.

Drugs, Vol. 66, Iss. 10, 2006-01 ,pp. : 1351-1359

Adis International

Access to resources Recommend Favorite

Intravenous Ibandronate: In the Treatment of Osteoporosis

By Croom Katherine F. Scott Lesley J.

Drugs, Vol. 66, Iss. 12, 2006-01 ,pp. : 1593-1601

Adis International

Access to resources Recommend Favorite